The European Medicines Agency (EMA) is reviewing the approval of the coronavirus vaccine by French pharmaceutical company Valneva for the EU market.
The EMA announced in Amsterdam on Wednesday that the company had submitted a corresponding application.
EMA’s experts had been reviewing all data from studies and trials on the vaccine, which had the official name VLA2001, since December.
“If the experts from the EMA give the green light, the European Commission still has to give its approval, but that is considered a formality.
“So far, five coronavirus vaccines have been approved in the EU.”
The Valneva vaccine was already approved for use in Britain in April.
VLA2001 is administered in two doses and is supposed to enable the body to protect itself against infection with the virus.
The preparation contains inactive viruses that cannot lead to infection and disease but stimulates the production of antibodies.
Dpa
